NICE recommends new treatment for unresectable or metastatic melanoma with a BRAF V600 mutation

Source: Pharma Field, February 2019

NICE recommends new treatment for adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Pierre Fabre welcomes the National Institute for Health and Care Excellence (NICE) decision to fund BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Between 2013 and 2015, there were around 15,400 cases of melanoma diagnosed in the UK, equating to approximately 42 every day. In 2015, melanoma was the fifth most common cancer in the UK, following breast, prostate, lung and bowel cancer. Metastatic melanoma is associated with low survival rates, with five-year survival gradually decreasing between stages I and IV.